Mexico Gets Its Own mRNA Factory

Moderna Inc. (MRNA) announced Tuesday it's entering a long-term strategic agreement with the Mexican government that goes beyond simply shipping vaccines across the border. The deal centers on building actual local manufacturing capabilities for mRNA technology, which is a bigger commitment than your typical supply contract.

The agreement includes a Memorandum of Understanding supporting "Plan Mexico," designed to create a full mRNA ecosystem in the country. This means Mexico gets access to Moderna's respiratory vaccine portfolio while building the infrastructure to eventually produce these medicines domestically.

Here's what makes this interesting: Moderna and the Mexican government will collaborate on local clinical research and development programs tailored to Mexico's specific health priorities. They're also working together to strengthen the country's pandemic preparedness framework, which became a pretty urgent priority after everyone's recent experience with COVID-19.

The technology transfer piece involves Laboratorios Liomont, a Mexican pharmaceutical company that will learn to manufacture Moderna's COVID-19 vaccine domestically. As part of the arrangement, Moderna committed to supplying up to 10 million doses for Mexico's 2025-2026 vaccination campaign.

This partnership follows recent regulatory approvals in Mexico for Moderna's COVID-19 vaccine for people aged six months and older, suggesting there's genuine demand for these products. CEO Stéphane Bancel highlighted how the partnership strengthens pandemic preparedness while addressing public health needs in the region.

The Stock Picture: Mixed Signals

Moderna shares present an interesting technical picture right now. The stock is trading 2.9% below its 20-day simple moving average, indicating some recent weakness. But zoom out a bit, and you'll see shares are sitting 37.7% above their 100-day moving average, which demonstrates longer-term momentum.

Over the past year, shares have climbed 31.63% and are currently positioned much closer to their 52-week highs than their lows. That's the good news.

The technical indicators tell a more complicated story. The RSI sits at 53.64, which is neutral territory—not oversold, not overbought, just hanging out in the middle. Meanwhile, MACD is below its signal line, which typically indicates bearish pressure. The combination suggests momentum could go either direction from here.

Traders are watching two key levels: resistance at $43.50 and support at $41.00.

What Wall Street Expects

Moderna reports earnings on February 13, 2026, and analysts are expecting challenging comparisons to last year. The consensus forecast calls for an EPS loss of $2.60, which would actually be an improvement from the $2.91 loss a year ago. Revenue estimates come in at $638.92 million, down from $966.00 million in the prior year period.

Analysts currently rate the stock as a Hold with an average price target of $50.52, suggesting modest upside from current levels. Recent analyst actions include UBS maintaining a Neutral rating while lowering its target to $34.00, Morgan Stanley keeping an Equal-Weight rating with a $28.00 target, and Jefferies initiating coverage with a Hold rating and $30.00 target.

The Momentum Story

One bright spot: Moderna scores 88.42 on momentum metrics, indicating the stock is outperforming the broader market despite mixed technical signals. This strong momentum setup contrasts with the cautious analyst ratings, creating an interesting dynamic heading into earnings.

The verdict? Moderna has genuine momentum working in its favor, but traders should stay alert as the February earnings report approaches. The Mexico partnership represents a strategic shift toward building sustainable international manufacturing infrastructure, which could pay dividends long after the headlines fade.

MRNA Price Action: Moderna shares were up 0.76% at $42.27 during premarket trading on Tuesday.